

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2004210891 B2**

- (54) Title
Progenitor cells from Wharton's jelly of human umbilical cord
- (51) International Patent Classification(s)
C12N 5/06 (2006.01)
- (21) Application No: **2004210891** (22) Date of Filing: **2004.02.10**
- (87) WIPO No: **WO04/072273**
- (30) Priority Data
- (31) Number (32) Date (33) Country
60/446,275 2003.02.11 US
- (43) Publication Date: **2004.08.26**
(44) Accepted Journal Date: **2008.09.25**
- (71) Applicant(s)
Dolores Baksh;John Davies;Rahul Sarugaser;Morris Hosseini;Antony Lickorish
- (72) Inventor(s)
Davies, John E.;Baksh, Dolores;Lickorish, Antony David Sutton;Sarugaser, Rahul;Hosseini, Morris
- (74) Agent / Attorney
Callinans, 1193 Toorak Road, Camberwell, VIC, 3124
- (56) Related Art
NAUGHTON BA et al (1997) FASEB Journal 11: A19
US 5,919,702 (PURCHIO et al) 6 July 1999
MITCHELL KE et al (2003) Stem Cells 21: 50-60

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
26 August 2004 (26.08.2004)

PCT

(10) International Publication Number
WO 2004/072273 A1

(51) International Patent Classification⁷: C12N 5/06

(21) International Application Number:
PCT/CA2004/000182

(22) International Filing Date: 10 February 2004 (10.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/446,275 11 February 2003 (11.02.2003) US

(71) Applicants and

(72) Inventors: DAVIES, John, E. [GB/CA]; 285 Garden Avenue, Toronto, Ontario M6R 1J4 (CA). BAKSH, Dolores [CA/CA]; 1080 Willowbank Trail, Mississauga, Ontario L4W 3H8 (CA). SARUGASER, Rahul [CA/CA]; 27 Ringwood Crescent, Toronto, Ontario M2J 1C8 (CA). HOSSEINI, Morris [DE/DE]; Billrothstr. 10, Braunschweig D-38116 (DE). LICKORISH, Antony, David, Sutton [AU/CA]; 25 St. Mary Street, Apartment 207, Toronto, Ontario M4Y 1R2 (CA).


(74) Agents: KAPLAN, Adrian, M. et al.; 20 Queen St. W., Suite 3202, Box 102, Toronto, Ontario M5H 3R3 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PROGENITOR CELLS FROM WHARTON'S JELLY OF HUMAN UMBILICAL CORD



(57) Abstract: Human progenitor cells are extracted from Wharton's jelly that lies within a perivascular zone of human umbilical cord. The progenitor cell population proliferates rapidly, and harbours both osteoprogenitor cells and MHC-/- cells, and is useful to grow and repair human tissues including bone.

WO 2004/072273 A1

WO 2004/072273 A1



Published:

— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

PROGENITOR CELLS FROM WHARTON'S JELLY OF HUMAN UMBILICAL CORD

FIELD OF INVENTION

5 This invention focuses on the harvesting of a population of rapidly proliferating human cells from the connective tissue of the umbilical cord (UC); the culture of such cells in osteogenic, or bone-forming conditions; the demonstration of a high percentage of cells within these populations that are immunologically incompetent, as shown by their lack of cell surface histocompatibility antigens; and the ability of these
10 cells to be used as a source of cells for various cell-based therapies.

BACKGROUND OF THE INVENTION

The UC is one of the first structures to form following gastrulation (formation of the three embryonic germ layers). As folding is initiated, the embryonic disc becomes connected, by the primitive midgut (embryonic origin) to the primitive yolk sac
15 (extra-embryonic origin) via the vitelline and allantoic vessels which in turn develop to form the umbilical vessels {Pereda, 2002 50 /id} {Tuchmann-Duplessis, 1972 77 /id} {Tuchmann-Duplessis, 1972 77 /id} {Haynesworth, 1998 51 /id}. These vessels are supported in, and surrounded by, what is generally considered a primitive mesenchymal tissue of primarily extra-embryonic derivation called Wharton's Jelly
20 (WJ) {Weiss, 1983 80 /id}. From this early stage, the UC grows, during gestation, to become the 30-50cm cord seen at birth. It can be expected therefore, that WJ contains not only the fibroblast-like, or myo-fibroblast-like cells which have been described in the literature (see below), but also populations of progenitor cells which can give rise to the cells of the expanding volume of WJ necessary to support the growth of the
25 cord during embryonic and fetal development.

WJ was first described by Thomas Wharton, who published his treatise *Adenographia* in 1656. It has subsequently been defined as a gelatinous, loose mucous connective tissue composed of cells dispersed in an amorphous ground substance composed of proteoglycans, including hyaluronic acid {Schoenberg, 1960 81 /id}, and different
30 types of collagens (Nanaev et al., 1997). The cells dispersed in the matrix have been described as "fibroblast-like" that are stellate in shape in collapsed cord and elongate in distended cord (Parry, 1970). Smooth muscle cells were initially observed within the matrix (Chacko and Reynolds, 1954), although this was disputed by Parry (1970)

who described them as somewhat “unusual fibroblasts” which superficially resemble smooth muscle cells. Thereafter, little work had been done on characterizing these cells until 1993 when Takechi et al. (1993) performed immunohistochemical investigations on these cells. They described the cells as “fibroblast-like” that were

5 “fusiform or stellate in shape with long cytoplasmic processes and a wavy network of collagen fibres in an amorphous ground substance” (Takechi et al., 1993). For the immunohistochemical staining, they used primary antibodies against actin and myosin (cytoplasmic contractile proteins), vimentin (characteristic of fibroblasts of embryonic mesenchyme origin) and desmin (specific to cells of myogenic origin) in order to

10 determine which types of myosin are associated with the WJ fibroblasts. They observed high levels of chemically extractable actomyosin; and although fibroblasts contain cytoplasmic actomyosin, they do not stain for actin or myosin, whereas the WJ fibroblasts stained positively for both. Additionally, positive stains for both vimentin and desmin were observed leading to the conclusion that these modified

15 fibroblasts in WJ were derived from primitive mesenchymal tissue (Takechi et al., 1993). A subsequent, more recent study by Nanaev et al. (1997) demonstrated five steps of differentiation of proliferating mesenchymal progenitor cells in pre-term cords. Their findings supported the suggestion that myofibroblasts exist within the WJ matrix. The immunohistochemical characterization of the cells of WJ, shows

20 remarkable similarities to that of pericytes which are known to be a major source of osteogenic cells in bone morphogenesis and can also form bone nodules referred to as colony forming unit-osteoblasts (CFU-O)(Aubin, 1998) in culture (Canfield et al., 2000).

Recent publications have reported methods to harvest cells from UC, rather than UC

25 blood. Mitchell et al. (Mitchell et al., 2003) describe a method in which they first remove and discard the umbilical vessels to harvest the remaining tissue. The latter, which will include both the remaining WJ (some of which will have been discarded with the vessels, since the umbilical vessels are entirely enveloped in WJ) and the amniotic epithelium, is then diced to produce small tissue fragments that are

30 transferred to tissue culture plates. These tissue fragments are then used as primary explants from which cells migrate onto the culture substratum.

In another publication, Romanov et al. (Romanov et al., 2003) indicate they were successful in isolating mesenchymal stem cell-like cells from cord vasculature,

although they also indicate their cultures do not contain cells from WJ. Specifically, they employ a single, 15min, collagenase digestion from within the umbilical vein, which yields a mixed population of vascular endothelial and sub-endothelial cells. Romanov et al. show that sparse numbers of fibroblast-like cells appear from this cell
5 harvest after 7 days.

Also, US patent 5,919,702 describes a method of isolating "pre-chondrocytes" from the WJ of human UC, and their use to produce cartilage. Particularly, the method comprises slicing open a one inch section of cord longitudinally, dissecting away the blood vessels and 'casing', which are then discarded, and collecting the WJ into a
10 sterile container where it was cut into 2-3mm³ sections for culturing. In a preferred method, cells are isolated by placing a 2-3mm³ section of the WJ on a glass slide on the bottom of a Petri dish, covering it with another slide, and culturing it for 10-12 days in order to allow the 'pre-chondrocytes' to migrate out to the culture dish surface.

15 It is an object of the present invention to provide a cell population comprising human progenitor cells.

It is another object of the present invention to provide a source from which human progenitor cells can be extracted.

It is a further object of the present invention to provide a method for the isolation of
20 human progenitor cells.

It is a further object of the present invention to provide human osteoprogenitor cells useful for the production of bone tissue.

It is a further object of the present invention to provide human immuno-incompetent progenitor cells useful therapeutically.

25 SUMMARY OF THE INVENTION

There has now been devised a procedure for extracting cells from Wharton's jelly of human umbilical cord, which yields a unique cell population characterized by rapid proliferation, the presence of osteoprogenitor and other human progenitor cells, including immuno-incompetent cells which display neither of the major
30 histocompatibility markers (human leukocyte antigen (HLA) double negative). The

cell population is a useful source of progenitor cells from which to grow bone and other connective tissues, and for autogenic and allogeneic transfer of progenitor cells to patients, for therapeutic purposes.

- 5 More particularly, and according to one aspect of the present invention, there is provided a method for obtaining a population of human progenitor cells, comprising the step of extracting said population from the Wharton's jelly in the perivascular zone of a human umbilical cord blood vessel, wherein the population comprises committed osteoprogenitor cells, and cells that are MHC I and MHC II negative, and
10 further wherein said population exhibits a doubling time that is more rapid than the doubling time of cells extracted from Wharton's jelly lying outside the perivascular zone.

- In another aspect the present invention provides an isolated cell population
15 comprising human progenitor cells, wherein the cell population (1) is extractable from the Wharton's jelly in the perivascular zone of a human umbilical cord blood vessel, (2) has a population doubling time that is more rapid than the doubling time of cells extracted from Wharton's jelly lying outside the perivascular zone, (3) comprises committed osteoprogenitor cells, and (4) comprises progenitor cells
20 having an MHC double negative phenotype.

- In another of its aspects, the present invention provides an isolated cell population comprising human progenitor cells having an MHC double negative phenotype.
25

It is preferred that a method for producing a cell population comprising human progenitor cells, comprises the step of culturing cells.

It is further preferred that a cell population comprises human progenitor cells.

It is further preferred that a method for producing bone cells, comprises the step of
5 culturing a cell population, to induce differentiation thereof into bone cells.

These and other aspects of the invention will now be described in greater detail with reference being had to the accompanying drawings, in which:

DESCRIPTION OF THE FIGURES

Figure 1 is a light micrograph representing the three distinct zones of tissue represented in the human UC;

5 Figure 2 is a representative illustration of the looped vessel in the collagenase solution;

Figure 3 is a light micrograph of the cells isolated from the WJ that have attached to the polystyrene tissue culture surface;

Figure 4 is a light micrograph illustrating the initial formation of a CFU-O;

Figure 5 is a light micrograph illustrating a mature CFU-O;

10 Figure 6 demonstrates tetracycline-labeled CFU-O's under UV fluorescence on a 35mm polystyrene tissue culture dish;

Figure 7 illustrates side by side a phase-contrast light micrograph and a fluorescence micrograph of the same tetracycline-labeled CFU-O;

15 Figure 8 is a scanning electron micrograph of a mature CFU-O on the tissue culture polystyrene surface;

Figure 9 is a scanning electron micrograph of a cross-section of a CFU-O exposing the underlying matrix;

Figure 10 is a scanning electron micrograph of the lightly mineralized collagen fibres located on the advancing edge of the CFU-O;

20 Figure 11 is a scanning electron micrograph of the non-collagenous matrix (seen as globules) laid down on the polystyrene interface by differentiating osteogenic cells;

Figure 12 is a scanning electron micrograph of heavily mineralized collagen that comprises the centre of a mature CFU-O;

25 Figure 13 illustrates the flow cytometry data demonstrating that WJ-derived cells are 77.4% MHC I and MHC II negative;

Figure 14 is a black and white reproduction of a Masson's trichome-stained transverse section of bone nodule showing the distribution of collagen within which cells have become entrapped (osteocytes), and multilayering of peripheral cells some of which are becoming surrounded by the elaborated extracellular matrix;

- 5 Figure 15 shows the potential expansion of the adherent perivascular WJ population in relation to the expansion of the committed osteoprogenitor subpopulation and total osteoprogenitor subpopulation;

- Figure 16 shows proliferation of the perivascular WJ cells from 0-144 hours illustrating a normal growth curve with a lag phase from 0-24 hrs, log phase from 24-
10 72 hours, and plateau phase from 72-120 hours. The doubling time during the entire culture period is 24 hours, while during log phase it is 16 hours; and

Figure 17 shows major histocompatibility complex (MHC) expression of the WJ cells shown over 5 passages, the change in their expression due to free-thawing, and subsequent expression due to reculture.

15 DETAILED DESCRIPTION OF THE INVENTION

The present invention provides an extract of Wharton's jelly (WJ), as a source of a rapidly proliferating cell population comprising human progenitor cells including osteoprogenitor cells, as well as immuno-incompetent cells.

- As used herein, the term "progenitor cells" refers to cells that will differentiate under
20 controlled and/or defined conditions into cells of a given phenotype. Thus, an osteoprogenitor cell is a progenitor cell that will commit to the osteoblast lineage, and ultimately form bone tissue when cultured under conditions established for such commitment and differentiation. A progenitor cell that is "immuno-incompetent" is a cell having a phenotype that is negative for surface antigens associated with class I
25 and class II major histocompatibility complexes (MHC). Such a progenitor cell is also referred to herein as an HLA double negative.

- The cell population extracted from WJ is also characterized by "rapid proliferation", which refers to the rate at which the extracted cells will grow relative to other known progenitor cell populations, under conditions that are standard for progenitor cell
30 expansion. As will be appreciated from the experimental results presented herein, and

as shown in Figure 16, the present progenitor cell population can double within at least about 25 hours and as quickly as 15 hours, and thus expands far more rapidly than other known osteoprogenitor cell populations and other progenitor cell populations extracted from WJ.

5 The cells and cell populations of the present invention can be obtained by extraction from WJ of human umbilical cord. Unlike the prior art, and in accordance with the present invention, such cells are extracted from the WJ that is associated with, i.e., proximal to, the exterior wall of the umbilical vasculature. The Wharton's jelly that is associated with or very near to the external surface of the cord vasculature lies within
10 a region termed the perivascular zone, and typically remains associated with the vasculature when the vessels are excised from the cord, as is done for instance either to extract Wharton's jelly from the cord, or to extract the vessels from the cord and associated Wharton's jelly. It has remarkably been found that the Wharton's jelly within this perivascular zone, and which has typically been discarded in prior art
15 practice, is a rich source of progenitor cells having the characteristics herein described. Accordingly, the present invention exploits the Wharton's jelly from this perivascular zone as a source for useful human progenitor cells.

To extract such Wharton's jelly from human umbilical cord, in a preferred embodiment, care is taking during the extraction process to avoid extracting cells of
20 the umbilical cord blood, epithelial cells or endothelial cells of the UC, and cells derived from the vascular structure of the cord, where vascular structure is defined as the tunicae intima, media and adventia of arterial or venous vessels. Obtaining an extract that is essentially free of these unwanted cells can be achieved by careful flushing and washing of the umbilical cord prior to dissection, followed by careful
25 dissection of the vessels from within the cord. The vessels can also be carefully pulled away from the surrounding cord tissue in which case the perivascular Wharton's jelly is removed with the vessels. It will be appreciated that, with care being taken to avoid extracting these unwanted cells, they may still be present to a small extent in the resulting extract. This is acceptable provided they occur at a frequency too low to
30 interfere with the observed results presented herein, i.e., observation of cell colonies derived from mesenchymal and specifically mesodermal origin, frequency and

rapidity of formation of CFU-O, and characterization of HLA phenotypes observed in the cultured population.

The WJ that lies within the perivascular zone is the Wharton's jelly proximal to the external wall of the umbilical vasculature, and lies typically within a zone extending
5 to about 3mm from the external wall of the vessels. Suitably, the target extraction zone can lie within about 2mm, e.g., about 1mm from the external wall of any one of the three vessels. The extraction of WJ from this region can be readily achieved using the technique described in the examples. In this technique the vessels are used as a carrier for the WJ, and the jelly-bearing vessels per se are used as the substrate from
10 which the progenitor cells are extracted. Thus, in embodiments of the invention, cord vessels bearing a thin coating of WJ are excised either surgically or manually from fresh umbilical cord that has been washed thoroughly to remove essentially all cord blood contaminants. The vessels bearing the proximal Wharton's jelly, or sections thereof, are then incubated at about 37°C in an extraction medium such as phosphate
15 buffered saline (PBS) containing an enzyme suitable for digesting the collagen matrix of the WJ in which the desired cells reside. For this purpose, digestion with a collagenase is suitable, at a concentration within the range from about 0.1mg/mL to 1.0mg/mL or more, e.g., 0.5mg/mL. During the extraction, the ends of the vessels are tied, or clipped, off and can be suspended above the extraction medium to avoid
20 contamination by agents contained within the vessel. It will thus be appreciated that the present Wharton's jelly extract is essentially free from cord blood cells and vessel endothelial cells.

After about 24 hours in the extraction medium, e.g., 12-36 hours, such as 18-24 hours, the vessels are removed, leaving a Wharton's jelly extract that contains human
25 progenitor cells. These cells are expanded under conditions standard for expansion of progenitor cells. The cells can, for instance, be selected on polystyrene to select for adherent cells, such as in polystyrene dishes or flasks and then maintained in a suitable culturing medium. In an embodiment of the invention, the extracted cells are cultured for expansion, with or without prior selection for adherent cells, under
30 conditions of stirred suspension, as described for instance by Baksh et al in WO02/086104, the disclosure of which is incorporated herein by reference.

The cells present in the extract can, either directly or after their expansion, be sorted using established techniques to provide expandable subpopulations enriched for cells of a given phenotype. Thus, the present invention further provides WJ extracted cell populations that are enriched for osteoprogenitor cells, cell populations that are
5 enriched for immuno-incompetent progenitor cells, and cell populations that are enriched for osteoprogenitor cells that are immuno-incompetent.

As is revealed in Figure 17, it has been found that the distribution of MHC markers within the progenitor cell population is altered by freeze-thawing. Upon passaging of fresh cells, the frequency of MHC double negative cells is relatively
10 constant/marginally increased. However, it has been found, as noted in the examples herein, that the frequency of MHC double negative cells in the progenitor population is increased significantly in cells plated following freezing. Thus, in the present progenitor cell population, cells of the MHC double negative phenotype are further characterized by the propensity to increase in frequency following freezing. Such
15 freezing is performed in the usual manner, by first preparing a cell aliquot, and then storing the cell preparation for the desired period.. It will be appreciated that such cells can be stored for many years if desired.

In an embodiment, the present invention thus further provides a method for producing MHC double negative progenitor cells, by obtaining a Wharton's jelly extract as
20 herein described, or an MHC double negative-enriched fraction thereof, subjecting the extract or fraction thereof to freezing, and then culturing the frozen cells. The resulting cells as noted are potentially useful to induce tissue formation or repair in human subjects.

The cell populations obtained from the extract or from a suitably enriched fraction
25 thereof, are useful either directly or following their expansion to provide differentiated cell populations. All of the procedures suitable for their fractionation and enrichment, and for their expansion are established in the prior art, and are exemplified herein. Expansion can proceed, for instance, in the presence of factors such as IL-3 and Stem Cell Factor, and similar agents known in the art. In one
30 embodiment, the present cell population, and particularly the osteoprogenitor cells therein, are subjected to differentiation using conditions established for the growth of bone tissue therefrom. Remarkably, a subpopulation of osteoprogenitor cells that

arise from the culturing of the present progenitor cell population, referred to as committed osteoprogenitors, have shown the ability to differentiate in the absence of osteogenic supplements. Alternatively, the osteoprogenitor cells are cultured in a medium supplemented with one or more agents that stimulate osteogenesis, such as dexamethasone. In addition, the progenitor cells can also be cultured with supplements suitable for stimulating differentiation into other mesenchymally-derived connective tissues (Caplan, 1991), including cartilage, muscle, tendon, adipose etc., all in accordance with standard practice in the art.

As a practical alternative to *in vitro* culturing of cells in the present cell population, it will be appreciated that the cells can be transplanted *in vivo* to induce the formation of a desired tissue directly within a patient. By this route, the *in situ* formation of bone is provided by implanting osteoprogenitor, for the benefit of patients suffering from various bone conditions, diseases and disorders, particularly including bone fracture and osteoporosis. The immuno-incompetent progenitor cells present in the cell population are particularly valuable in this respect, given the substantially reduced rejection response that can be expected following their implantation.

Embodiments of the invention are described in the following examples.

Harvest of Progenitor Cells from Human Wharton's Jelly

The UCs were collected from full-term caesarian section infants immediately upon delivery at Sunnybrook & Women's College Hospital, Toronto, Canada. The UC was transferred by the surgeon into a sterile vessel containing medium (75% α -MEM, 15% Fetal Bovine Serum (FBS), 10% antibiotics), and immediately transported to our laboratories at the Institute of Biomaterials & Biomedical Engineering, University of Toronto.

All procedures from this point on were performed aseptically in a biological safety cabinet. The UC was washed in Phosphate Buffered Saline (PBS) ($-Mg^{2+}$, $-Ca^{2+}$) three times to remove as much of the UC blood as possible, and transferred back into a container with medium. A length of approximately 6 cm of cord was cut with sterile scissors and placed onto a sterile cork dissection board. The remaining cord (30-45 cm) was returned to the medium-filled container and placed into an incubator at 37°C. The 6 cm section of cord was 'twisted' against its helix, and pinned at both

ends to reveal a smooth and straight surface of the UC epithelium. Using fine scissors, the UC was cut approximately 1-2 mm deep along its length to reveal the WJ. Starting with each 'flap' of cut epithelium, the WJ was teased from its inner surface using the blunt edge of a scalpel, and the teased away epithelium (approximately 0.5mm thick) was pinned down. This procedure resulted in the WJ being exposed, and with its three vessels embedded in it running straight from end to end rather than helically along its longitudinal axis. Care was taken to constantly bathe the section with 37°C PBS. Isolating one of the ends of a vessel with tweezers, it was teased away from the WJ along its length until it was free of the bulk of the WJ matrix. Alternatively, the middle of the vessel could be dissected from the matrix, held with tweezers, and teased from the matrix in each direction toward its ends. Once freed by either method, the vessel was surrounded with approximately 1-2mm of the cell-bearing WJ matrix. The dissected vessel was then clipped at both ends with either a surgical clamp, mosquito clip or sutured to create a 'loop,' blocking the passage of fluid either into or out of the vessel. The 'loop' was immediately placed along with the scissors into a 15ml tube containing a 0.5mg/ml collagenase solution with PBS ($-Mg^{2+}$, $-Ca^{2+}$), and placed into an incubator at 37°C. The remaining two vessels were dissected in a similar fashion, looped, and also placed in the collagenase solution in the incubator. Subsequent to the removal of the vessels, strips of WJ could easily be dissected off the epithelium and placed into 15 ml tubes with the collagenase solution. The remaining epithelial layer was then disposed of in a biohazard waste container. The same protocol was used with the remaining 30-45 cm of UC, producing 15 to 25 tubes with either 'loops' or WJ strips.

Initiation of Wharton's Jelly Progenitor Cell Cultures

After 18-24 hours, the 'loops' were removed with the aid of their attached suspension clamp or suture and a pipette, and the remaining suspensions were plated directly onto T-75 cm² tissue culture polystyrene dishes, and allowed to sit for 72 hours in order to allow the cells to attach to the polystyrene surface. The medium was then changed every two days.

The attached cells were passaged using 1% trypsin solution after 7 days, at which point they exhibited 80-90% confluency, as observed by light microscopy, and there was evidence of 'mineralized' aggregate formation, as revealed under phase

microscopy and indicated by expected changes in optical properties. Upon passage, cells were plated either in 35mm tissue culture polystyrene dishes or 6 well plates at 1×10^4 cells/cm² in 75% α -MEM, 15% FBS, 10% antibiotics and treated with 10^{-8} M Dex, 5mM β -GP and 50 μ g/ml ascorbic acid to test the osteogenic capacity of these
5 cells. These plates were observed on days 2, 3, 4 and 5 of culture for CFU-O otherwise referred to as 'bone nodule' formation.

Another useful approach to obtaining the Wharton's jelly progenitor cell cultures has been adopted, using the following protocol:

1. Obtain sterile umbilical cord (UC) from caesarian-section patient and transport
10 to biological safety cabinet in media (80% α -MEM, 20% antibiotics)
2. Wash the UC 2x in sterile 37°C phosphate buffered saline (PBS)
3. Cut the UC into approximately 1-2 inch sections with a sharp pair of scissors
4. Wash each section of UC 2x in sterile 37°C PBS to remove as much residual umbilical cord blood (UCB) as possible.
- 15 5. Isolate one of the UC sections on a dry sterile dish
6. Using two sets of forceps, grasp the epithelium approximately 2mm apart, and pull away from each other, tearing the epithelium.
7. Grasping the epithelium along the length of the UC section, continue to tear the epithelium away, exposing the WJ underneath
- 20 8. Similarly to step 6, continue tearing the epithelium away in 'strips' until approximately half of the epithelium has been torn away.
9. The umbilical vessels should be clearly visible through the WJ, and the ends loose on the cut edges of the UC section.
- 25 10. By grasping a remaining part of the epithelium with one set of forceps, and the end of a vessel with the other, the vessel can be 'pulled' from the bulk WJ with its surrounding PVWJ.

11. This process is repeated with each vessel, until all three are free of the underlying WJ matrix.
12. Once released, each vessel is placed into 37°C PBS.
13. Steps 5-12 are repeated with each section of UC until all the vessels have been isolated in a sterile 37°C PBS-filled beaker.
14. Then, by placing each vessel individually on a clean, sterile surface, the ends can be ligated together with a suture using a double knot into a 'loop'
15. Once all of the vessels have been ligated into loops, the loops are placed into a 1mg/ml collagenase solution in a sterile 50ml tube
16. The 50ml tube is placed into a rotator in a 37°C, 5%CO₂ incubator overnight.
17. The following day, the collagenase is inactivated with 1ml fetal bovine serum (FBS), and the loops removed from the suspension.
18. The remaining suspension is diluted with PBS, centrifuged at 1150rpm for 5 minutes, and the supernatant removed.
19. The cells remaining in the pellet are resuspended in supplemented media (SM) (75% α -MEM, 15% FBS, 20% antibiotics), and aliquot is counted on a hemocytometer.
20. The cell suspension is then plated onto a T-25 tissue-culture polystyrene flask, and allowed to proliferate.
21. The SM is changed every 2 days until the cells reach sub-confluence (1-2 weeks), at which point they are sub-cultured (passaged).

PROGENITOR ASSAYS

Cell Proliferation Assay

During the weekly passage procedure (occurring every 6 days), aliquots of 2×10^5 cells were plated into 20 T-25 cm² tissue culture polystyrene flasks. On days 2, 4, 6, 10 and 12 of culture, four of the T-25 flasks were passaged and the cells were counted. The exponential expansion of these cells was plotted, and the mean

- doubling time for the cells in these cultures was calculated. Results are shown in Figure 16. It will be noted that the doubling time for the PVWJ cell culture is about 24 hours across the entire culturing period. During the log phase, the doubling time is a remarkable 16 hours. This compares with literature reported doubling times of about 33 hours for bone marrow mesenchymal cells ((Conget,P, J J Minguell, 1999, Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells: Journal of Cell Physiology, v. 181, p. 67-73.), and about 3.2 days for mesenchymal stem cells derived from adipose tissue (Sen,A, J.Cell Biochem., v. 81, p. 312-319.)
- As show in Figure 15, the perivascular Wharton's Jelly (PVWJ)-derived progenitors comprise different sub-populations of progenitor cells. Within this population, there are the so-called "committed" osteoprogenitor cells characterized by an ability to form bone nodules, as shown herein, in the absence of the culturing supplements normally required to induce such differentiation, such as culturing in the presence of dexamethasone. These committed osteoprogenitors thus differentiate spontaneously to form bone nodules. Also within the PVWJ progenitor population are osteoprogenitor cells that can be induced to form bone nodules, when cultured in the presence of the required factors, such as dexamethasone, β -glycerophosphate and ascorbic acid. Thus, is the "total osteoprogenitor" sub population graphed in Figure 15 includes the "committed osteoprogenitor" population, as well as the "uncommitted osteoprogenitor" population, and reveals the total number of cells that can be induced to differentiate down the osteogenic lineage. The actual ratio between the "committed" and "uncommitted" population is approximately 1:1, and so the ratio between the "total osteoprogenitor" population and the "committed osteoprogenitor" population is about 2:1. Analysis of the bone forming properties of the progenitors was performed as noted below.

CFU-O Assay

- During the weekly passage procedure, aliquots of test cell populations were directly plated on tissue-culture polystyrene in bone forming medium containing 75% α -MEM, 15% FBS (StemCell Batch #: S13E40), 10% antibiotic stock solution containing penicillin G (167 units/ml), gentamicin (50 μ g/ml) and amphotericin B (0.3 μ g/ml), and Dex (10^{-8} M), β -glycerophosphate (5mM) and L-ascorbic acid

(50ug/ml), at a cell seeding density of 1×10^4 cells/cm². Cultures were re-fed every two days for a period of 12 days. The cultures were maintained until mineralized nodular areas, detected as bone nodules, were observed (usually 3 days) at which point the cultures were re-fed with tetracycline containing medium at the last culture re-feed, then fixed in Karnovsky's fixative and prepared for analysis. A Leitz Aristoplan microscope (Esselte Leitz GmbH & Co KG, Stuttgart, Germany) was used to visualize the tetracycline labelled cultures under phase contrast as well as UV fluorescence and a Hitachi S-2000 scanning electron microscope at an accelerating voltage of 15 kV was used to generate images to demonstrate the presence of morphologically identifiable bone matrix.

DATA ANALYSIS

Tetracycline Stain

Tetracycline (9 µg/ml) was added to the cultures prior to termination. At termination, the cells were fixed in Karnovsky's fixative overnight and then viewed by UV-excited fluorescence imaging for tetracycline labeling of the mineral component of the nodular areas.

Scanning Electron Microscopy (SEM)

Representative samples of CFU-O cultures were prepared for SEM by first placing them in 70%, 80%, 90% and 95% ethanol for 1 hour, followed by immersion in 100% ethanol for 3 hours. They were then critical point dried. A layer of gold approximately 3 nm layer was sputter coated with a Polaron SC515 SEM Coating System onto the specimens, which were then examined at various magnifications in a Hitachi S-2000 scanning electron microscope at an accelerating voltage of 15 kV. The images generated are used to demonstrate the presence of morphologically identifiable bone matrix.

Flow cytometry for HLA-typing

Test cell populations of $>1 \times 10^5$ cells were washed in PBS containing 2% FBS (StemCell Batch #: S13E40) and re-suspended in PBS + 2% FBS with saturating concentrations (1:100 dilution) of the following conjugated mouse IgG1 HLA-A,B,C-PE and HLA-DR,DP,DQ-FITC for 30 minutes at 4°C. The cell suspension was washed twice with PBS + 2% FBS, stained with 1µg/ml 7-AAD (BD Biosciences) and re-suspended in PBS + 2% FBS for analysis on a flow cytometer (XL, Beckman-

Coulter, Miami, FL) using the ExpoADCXL4 software (Beckman-Coulter). Positive staining was defined as the emission of a fluorescence signal that exceeded levels obtained by >99% of cells from the control population stained with matched isotype antibodies (FITC- and PE-conjugated mouse IgG1, κ monoclonal isotype standards, BD Biosciences). For each sample, at least 10,000 list mode events were collected. All plots were generated in EXPO 32 ADC Analysis software.

RESULTS

Light micrographs of bone nodule Colonies

Figures 3, 4 and 5 illustrate CFU-O's that were present in the cultures on day 3 and day 5. They demonstrated the confluent layer of "fibroblastic-like" cells surrounding a nodular area represented by an 'aggregation' of polygonal cells that were producing the bone-matrix. These CFU-O's were observed in both the Dex (+) and Dex (-) cultures, and displayed similar morphology over successive passages.

Tetracycline Labeling of CFU-O Cultures

Tetracycline labeling of cultures was used for labeling newly formed calcium phosphate associated with the biological mineral phase of bone. The tetracycline labeling of the cultures coincide with the mineralized nodular areas, which is visualized by exposing the cultures to UV light. Figures 6 and 7 depict tetracycline labeled CFU-O cultures of Day 3 and Day 5 cultures of WJ progenitor cells. These images were generated by UV-excited fluorescence imaging, and photographed.

Scanning Electron Microscopy

The CFU-O's were observed under SEM for formation of mineralized collagen matrix which demonstrates the formation of the CFU-O's from the initial stages of collagen formation through to the densely mineralized matrix in the mature CFU-O. Figures 8, 9, 10, 11, 12 and 14 represent scanning electron micrographs of the CFUOs.

Flow Cytometry & HLA-typing

The flow cytometry, identifying cell-surface antigens representing both Major Histocompatibility Complexes (MHCs) demonstrated 77.4% of the population of isolated cells as MIIC⁺. Figure 13 illustrates the flow cytometry results in relation to the negative control. Figure 17 shows the impact of freeze-thawing on the frequency

of MHC -/- cells in the progenitor population. The effect of freeze-thawing was studied as follows:

Test cell populations of $>1 \times 10^5$ cells were washed in PBS containing 2% FBS and re-suspended in PBS + 2% FBS with saturating concentrations (1:100 dilution) of the following conjugated mouse IgG1 HLA-A,B,C-PE (BD Biosciences #555553 , Lot M076246) (MHC I), HLA-DR,DP,DQ-FITC (BD Biosciences #555558 , Lot M074842) (MHC II) and CD45-Cy-Cychrome (BD Biosciences # 555484, Lot 0000035746) for 30 minutes at 4°C. The cell suspension was washed twice with PBS + 2% FBS and re-suspended in PBS + 2% FBS for analysis on a flow cytometer (XL, Beckman-Coulter, Miami, FL) using the ExpoADCXL4 software (Beckman-Coulter). Positive staining was defined as the emission of a fluorescence signal that exceeded levels obtained by >99% of cells from the control population stained with matched isotype antibodies (FITC-, PE-, and Cy-cychrome-conjugated mouse IgG1, κ monoclonal isotype standards, BD Biosciences), which was confirmed by positive fluorescence of human BM samples. For each sample, at least 10,000 list mode events were collected. All plots were generated in EXPO 32 ADC Analysis software.

Sub-culture & cell seeding

The attached cells were sub-cultured (passaged) using 0.1% trypsin solution after 7 days, at which point they exhibited 80-90% confluency as observed by light microscopy. Upon passage, the PVWJ (perivasculature zone Wharton's jelly) cells were observed by flow cytometry for expression of MHC-A,B,C, MHC-DR,DP,DQ, and CD45. They were then plated in T-75 tissue culture polystyrene flasks at 4×10^3 cells/cm² in SM, and treated with 10^{-8} M Dex, 5mM β -GP and 50 μ g/ml ascorbic acid to test the osteogenic capacity of these cells. These flasks were observed on days 2, 3, 4, 5 and 6 of culture for CFU-O or bone nodule, formation. Any residual cells from the passaging procedure also were cryopreserved for future use.

Cryopreservation of cells

Aliquots of 1×10^6 PVWJ cells were prepared in 1ml total volume consisting of 90% FBS, 10% dimethyl sulphoxide (DMSO) (Sigma D-2650, Lot# 11K2320), and pipetted into 1ml polypropylene cryo-vials. The vials were placed into a -70°C freezer overnight, and transferred the following day to a -150°C freezer for long-term

storage. After one week of cryo-preservation, the PVWJ cells were thawed and observed by flow cytometry for expression of MHC-A,B,C, MHC-DR,DP,DQ, and CD45. A second protocol was used in which the PVWJ cells were thawed after one week of cryopreservation, recultured for one week, sub-cultured then reanalyzed by
5 flow cytometry for expression of MHC-A,B,C, MHC-DR,DP,DQ, and CD45.

The results are presented in Figure 17. It will be noted that the frequency of MHC-/- within the fresh cell population is maintained through several passages. When fresh cells are frozen after passaging, at -150C for one week and then immediately analyzed for MHC phenotype, this analyzed population displays a remarkably enhanced
10 frequency of cells of the MHC -/- phenotype. Thus, and according to an embodiment of the present invention, cells of the MHC -/- phenotype can usefully be enriched from a population of PVWJ cells by freezing. Still further enrichment is realized upon passaging the cultures of the previously frozen cells. The frozen PVWJ cells per se are potentially very useful in human therapy, given their immuno-incompetence.

15 As noted, the PVWJ progenitor cell population may also be exploited to give rise to mesenchymal cells and tissues other than bone, by culturing under conditions appropriate for such differentiation. To generate adipocytes, for instance, the progenitors are prepared at a concentration of 10^4 cells/cm² and plated in 35 mm tissue culture dishes. The cells are maintained in Preadipocyte Medium (PM)
20 (DMEM/Ham's F-10 (1:1, vol/vol), 10% fetal calf serum, 15 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin, 0.25 µg/ml amphotericin B) for 3 days. After 3 days, the PM is removed, and the cells are fed with Adipogenic medium (DMEM/Ham's F-10 nutrient broth, 1:1, v/v; HEPES buffer (15 mM); Fetal Bovine Serum (3%); Biotin (33 µM), Pantothenate (17 µM), human insulin (100 nM),
25 dexamethasone (0.5 µM), PPARγ agonist (1 µM) and antibiotics), and cultured for 3 days. After the 3 day induction, the Adipogenic medium is removed, and the cultures are maintained in Adipocyte Medium (AM) (DMEM/Ham's F-10 (1:1, vol/vol), 3% fetal calf serum, 1 µM dexamethasone, 100 nM human insulin, 33 µM D-biotin, 17 µM Na-pantothenate, 15 mM HEPES, 100 U/ml penicillin, 100 µg/ml streptomycin,
30 0.25 µg/ml amphotericin B), with regular feeding every 3 days, ensuring to only remove half the medium, replenishing with an equal volume of AM since adipocytes will float if all the media is removed. After four feedings (12 days), cells appear

rounded with lipid droplets. Positive identification of differentiated mesenchymal cells into adipocytes can be confirmed by staining with Oil Red O and Nile Red.

Similarly, chondrocytes may be generated using cell suspensions prepared at a concentration of 10^4 cells/cm² and plated in 35 mm tissue culture dishes. To promote chondrogenic cells are cultured without serum and with transforming growth factor- β 3. The cell pellets develop a multilayered matrix-rich morphology and histologically show an increased proteoglycan-rich extracellular matrix during culture.

To generate myoblasts, cell suspensions are prepared at a concentration of 10^4 cells/cm² and plated in 35 mm tissue culture dishes. The cells are maintained in MCDB 120 medium completed with 15% fetal bovine serum (FBS) for 1 week (myoblast proliferation medium, MPM). At 1 week, the serum level in the basal medium (MPM) is dropped to 2% (myoblast differentiation medium, MDM) and the cultures are terminated after 7 days.

The cultures are re-fed 3-times a week with appropriate culture medium.

It will thus be appreciated that the present invention provides human progenitor cells having properties useful in the production of various connective tissues including bone, and further provides progenitor cells that are immune incompetent and ideal for transplantation into human patients to treat connective tissue conditions including bone diseases and disorders. The human progenitor cells are generated from extracts of a particular zone of human umbilical cord Wharton's jelly, termed the perivascular zone, extending proximally from the external wall of the cord vessels. The cell population extracted from this zone displays remarkable properties, including rapid proliferation, changes in cell morphology, as witnessed by the formation of cell colonies occurring before day 7 in all subcultured flasks (approximately 7-10 doublings) and the appearance of bone nodule formation without the addition of osteogenic supplements to the culture medium, as well as relatively high frequency of MHC double negative cells, the frequency of which is increased upon culturing of cells that have been frozen.

The following references are incorporated herein by reference:

Aubin, JE, 1998, Bone stem cells: J Cell Biochem Suppl, v. 30-31, p. 73-82.

- Beckstead, JH, D F Bainton, 1980, Enzyme histochemistry on bone marrow biopsies: reactions useful in the differential diagnosis of leukemia and lymphoma applied to 2-micron plastic sections: *Blood*, v. 55, p. 386-394.
- Beckstead, JH, P S Halverson, C A Ries, D F Bainton, 1981, Enzyme histochemistry
5 and immunohistochemistry on biopsy specimens of pathologic human bone marrow: *Blood*, v. 57, p. 1088-1098.
- Canfield, AE, M J Doherty, B A Ashton, 2000, Osteogenic potential of vascular pericytes, in JE Davies (ed), *Bone Engineering*: Toronto, EM Squared, Inc., p. 143-151.
- 10 Caplan, AI, 1991, Mesenchymal stem cells: *J Orthop. Res*, v. 9, p. 641-650.
- Chacko, AW, S R M Reynolds, 1954, Architecture of distended and nondistended human umbilical cord tissues, with special reference to the arteries and veins.: *Carnegie Institution of Washington, Contributions to Embryology*, v. 35, p. 135-150.
- Friedenstein, AJ, J F Gorskaja, N N Kulagina, 1976, Fibroblast precursors in normal
15 and irradiated mouse hematopoietic organs: *Exp Hematol*, v. 4, p. 267-274.
- Mitchell, KE, M L Weiss, B M Mitchell, P Martin, D Davis, L Morales, B Helwig, M Beerenstrauch, K Abou-Easa, T Hildreth, D Troyer, 2003, Matrix Cells from Wharton's Jelly Form Neurons and Glia: *Stem Cells*, v. 21, p. 50-60.
- Nanaev, AK, G Kohnen, A P Milovanov, S P Domogatsky, P Kaufmann, 1997,
20 *Stromal Differentiation and Architecture of the Human Umbilical Cord: Placenta*, v. 18, p. 53-64.
- Parry, EW, 1970, Some electron microscope observations on the mesenchymal structures of full-term umbilical cord: *Journal of Anatomy*, v. 107, p. 505-518.
- Pereda, J, P M Motta, 2002, New advances in human embryology: morphofunctional
25 relationship between the embryo and the yolk sac: *Medical Electron Microscopy*, v. 32, p. 67-78.

Romanov, YA, V A Svintsitskaya, V N Smirnov, 2003, Searching for Alternative Sources of Postnatal Human Mesenchymal Stem Cells: Candidate MSC-Like Cells from Umbilical Cord: Stem Cells, v. 21, p. 105-110.

5 Schoenberg, MD, A Hinman, R D Moore, 1960, Studies on connective tissue V, Feber formation in Wharton's Jelly.: Laboratory Investigation, v. 9, p. 350-355.

Takechi, K, Y Kuwabara, M Mizuno, 1993, Ultrastructural and Immunohistochemical Studies of Wharton's Jelly Umbilical Cord Cells: Placenta, v. 14, p. 235-245.

10

Tuchmann-Duplessis, H, G David, P Haegel, 1972, Illustrated Human Embryology, New York, Springer-Verlag, p. 54-61.

15 Weiss, L, 1983, Histology: cell and tissue biology, New York, Elsevier Biomedical, p. 997-998.

Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps
20 but not the exclusion of any other integer or step or group of integers or steps.

The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form or suggestion that the prior art forms part of the common general knowledge in Australia.


25

The claims defining the invention are as follows:

1. A method for obtaining a population of human progenitor cells, comprising the step of extracting said population from the Wharton's jelly in the perivascular
5 zone of a human umbilical cord blood vessel, wherein the population comprises committed osteoprogenitor cells, and cells that are MHC I and MHC II negative, and further wherein said population exhibits a doubling time that is more rapid than the doubling time of cells extracted from Wharton's jelly lying outside the perivascular zone.
10
2. The method according to claim 1, wherein the extraction step is performed on a Wharton's jelly-bearing blood vessel that has been excised from human umbilical cord.
- 15 3. The method according to claim 1 or claim 2, wherein said Wharton's jelly is subjected to enzymatic digestion in a suitable cell extraction medium.
4. The method according to claim 3, wherein the enzymatic digestion results in the release of cells from the collagen matrix of said Wharton's jelly.
20
5. The method according to claim 4, wherein the step of extracting the cells is performed at 37C in phosphate buffered saline and 0.1-1.0 mg/mL for a period of 12 to 36 hours.
- 25 6. The method according to any one of claims 1-5, wherein the population of human progenitor cells is essentially free from cells derived from the vascular structure of the umbilical cord.
7. A method for producing a cell population comprising human progenitor cells,
30 comprising the step of culturing cells obtained by the method according to any one of claims 1-6.

8. The method according to any preceding claim, comprising the further step of treating said population to enrich for osteoprogenitor cells.
- 5 9. The method according to any one of claims 1-7, comprising the further step of treating said population to enrich for progenitor cells having an MHC double negative phenotype.
- 10 10. The method according to claim 9, wherein said population is subjected to a freeze/thaw step to enrich for progenitor cells having the MHC double negative phenotype.
11. A cell population comprising human progenitor cells, whenever obtained by the method according to any one of claims 1-10.
- 15 12. An isolated cell population comprising human progenitor cells, wherein the cell population (1) is extractable from the Wharton's jelly in the perivascular zone of a human umbilical cord blood vessel, (2) has a population doubling time that is more rapid than the doubling time of cells extracted from Wharton's jelly lying outside the perivascular zone, (3) comprises committed osteoprogenitor cells, and (4) comprises progenitor cells having an MHC double negative phenotype.
- 20 13. A cell population which is an isolated subpopulation of the cell population according to claim 12, wherein said subpopulation is enriched for osteoprogenitor cells.
- 25 14. A cell population which is an isolated subpopulation of the cell population according to claim 12, wherein said subpopulation is enriched for progenitor cells having an MHC double negative phenotype.
- 30 15. A cell population according to any one of claims 11-14, in a cryopreserved state.

16. A method for producing bone cells, comprising the step of culturing a cell population according to any one of claims 11-13 to induce differentiation thereof into bone cells.
5
17. The method according to claim 16, wherein the cell population is cultured in the absence of osteogenic supplements.
18. A method for producing adipocytes, comprising the step of culturing a cell population according to any one of claims 11-13 under conditions conducive to differentiation into adipocytes.
10
19. A method for producing myoblasts, comprising the step of culturing a cell population according to any one of claims 11-13 under conditions conducive to differentiation into myoblasts.
15
20. The use of a cell population according to any one of claims 11-15 in the preparation of a medicament for the treatment of a medical condition, disease or disorder.
20
21. An extract comprising human progenitor cells whenever obtained by the method according to any one of claims 1-6.
22. A method for obtaining a population of human progenitor cells substantially as hereinbefore described with reference to any one of the drawings.
25
23. An isolated cell population substantially as hereinbefore described with reference to any one of the drawings.
30



2/15




Figure 2

3/15




Figure 3




Figure 4

4/15




Figure 5




Figure 6

5/15



Figure 7

6/15




Figure 8

7/15



Figure 9




Figure 10

9/15




Figure 11

10/15




Figure 12




Figure 13




Figure 14




Figure 15




Figure 16




Figure 17